This study tests a new drug (JAB-21822) combined with standard chemotherapy and bevacizumab in people with advanced colorectal cancer that has a specific KRAS G12C mutation. The goal is to see if this combination can shrink tumors or slow the disease in patients who have already …
Phase: PHASE1 • Sponsor: Jian Li • Aim: Disease control
Last updated May 17, 2026 06:44 UTC